SCHEMBL18220189

SCHEMBL18220189

COCCNC(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.43
PRKD1 Q15139 3/20 0.39
RXFP1 Q9HBX9 3/20 0.38
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
ERN1 O75460 1/20 0.35
ATM Q13315 1/20 0.34
CTSK P43235 4/20 0.34
CTSL P07711 3/20 0.34
CTSB P07858 2/20 0.34
CTSS P25774 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
PLA2G1B P04054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220172 0.93 APP (0.42) APPRXFP1KMT2AMEN1KDM4E
SCHEMBL19293972 0.92 APP (0.39) APPPRKD1RXFP1ERN1CTSK
SCHEMBL18220177 0.91 APP (0.44) APPKMT2AMEN1ERN1CTSK
SCHEMBL18219989 0.85 APP (0.49) APPPRKD1RXFP1KMT2AMEN1
SCHEMBL24068460 0.85 APP (0.38) APPRXFP1KMT2AMEN1ERN1
SCHEMBL17120769 0.85 CTSK (0.35) APPPRKD1ERN1CTSKCTSL
SCHEMBL18220289 0.85 CTSK (0.37) APPPRKD1ERN1CTSKCTSL
SCHEMBL21226381 0.83 APP (0.40) APPKMT2AMEN1ERN1ATM
SCHEMBL18220176 0.83 APP (0.43) APPPRKD1RXFP1KMT2AMEN1
SCHEMBL18220164 0.83 APP (0.51) APPRXFP1KMT2AMEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885PRKD1 3969/4885RXFP1 4279/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885PRKD1 3969/4885RXFP1 4279/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885PRKD1 4009/4885RXFP1 4325/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885PRKD1 4009/4885RXFP1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.